Immutep Limited (IMMP)
NASDAQ: IMMP · IEX Real-Time Price · USD
1.940
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
1.980
+0.040 (2.06%)
Pre-market: Jul 22, 2024, 7:28 AM EDT
Immutep Revenue
Immutep had revenue of $4.58M in the twelve months ending December 31, 2023. In the fiscal year ending June 30, 2023, Immutep had annual revenue of $3.59M.
Revenue (ttm)
$4.58M
Revenue Growth
-23.58%
P/S Ratio
53.54
Revenue / Employee
$147,637
Employees
31
Market Cap
245.05M USD
Revenue Chart
* The company reports in AUD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 3.59M | -1.11M | -23.58% |
Jun 30, 2022 | 4.69M | 1.71M | 57.30% |
Jun 30, 2021 | 2.98M | -8.40M | -73.78% |
Jun 30, 2020 | 11.38M | 6.11M | 115.75% |
Jun 30, 2019 | 5.27M | -172.67K | -3.17% |
Jun 30, 2018 | 5.45M | 2.20M | 67.77% |
Jun 30, 2017 | 3.25M | 1.74M | 114.92% |
Jun 30, 2016 | 1.51M | -102.31K | -6.34% |
Jun 30, 2015 | 1.61M | -1.35M | -45.47% |
Jun 30, 2014 | 2.96M | -704.67K | -19.24% |
Jun 30, 2013 | 3.66M | -632.41K | -14.72% |
Jun 30, 2012 | 4.30M | 3.15M | 275.71% |
Jun 30, 2011 | 1.14M | 699.68K | 157.75% |
Jun 30, 2010 | 443.55K | 420.00K | 1,783.04% |
Jun 30, 2009 | 23.56K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Semler Scientific | 65.88M |
AVITA Medical | 51.50M |
Utah Medical Products | 49.04M |
Mersana Therapeutics | 38.30M |
Senseonics Holdings | 23.30M |
Cibus | 2.32M |
Atai Life Sciences | 277.00K |
Sera Prognostics | 206.00K |
IMMP News
- 10 days ago - Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression - GlobeNewsWire
- 19 days ago - Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results - GlobeNewsWire
- 27 days ago - Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer - GlobeNewsWire
- 6 weeks ago - Immutep successfully completes institutional placement and institutional component of entitlement offer - GlobeNewsWire
- 7 weeks ago - Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial - GlobeNewsWire
- 2 months ago - Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 - GlobeNewsWire
- 2 months ago - Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma - GlobeNewsWire
- 3 months ago - Immutep Quarterly Activities Report Q3 FY24 - GlobeNewsWire